The Changing View of High-Grade Serous Ovarian Cancer

被引:131
|
作者
Berns, Els M. J. J. [1 ,2 ]
Bowtell, David D. [1 ,3 ]
机构
[1] Peter MacCallum Canc Ctr, Canc Genom & Genet Program, Melbourne, Vic 8006, Australia
[2] Erasmus MC Daniel Hoed Canc Ctr, Dept Med Oncol, Rotterdam, Netherlands
[3] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia
关键词
FALLOPIAN-TUBE; PLATINUM RESISTANCE; GENE-EXPRESSION; CARCINOMA; MUTATIONS; CHEMOTHERAPY; CELL; CARCINOGENESIS; ACTIVATION; EVOLUTION;
D O I
10.1158/0008-5472.CAN-11-3911
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The classification of epithelial ovarian cancer has been substantially revised, with an increased appreciation of the cellular origins and molecular aberrations of the different histotypes. Distinct patterns of signaling-pathway disruption are seen between and within histotypes. Large-scale genomic studies of high-grade serous cancer, the most common histotype, have identified novel molecular subtypes that are associated with distinct biology and clinical outcome. High-grade serous cancers are characterized by few driver point mutations but abundant DNA copy number aberrations. Inactivation of genes associated with DNA damage repair underlies responses to platinum and PARP inhibitors. Here we review these recent developments. Cancer Res; 72(11); 2701-4. (C)2012 AACR.
引用
收藏
页码:2701 / 2704
页数:4
相关论文
共 50 条
  • [1] The genesis and evolution of high-grade serous ovarian cancer
    Bowtell, David D. L.
    NATURE REVIEWS CANCER, 2010, 10 (11) : 803 - 808
  • [2] The genesis and evolution of high-grade serous ovarian cancer
    David D. L. Bowtell
    Nature Reviews Cancer, 2010, 10 : 803 - 808
  • [3] Proteogenomic characterization of high-grade serous ovarian cancer
    McDermott, Jason E.
    Payne, Samuel
    Ray, Debjit
    Petyuk, Vladislav
    Moore, Ronald
    Gritsenko, Marina
    Smith, Richard
    Rodland, Karin
    CANCER RESEARCH, 2016, 76
  • [4] Cell Origins of High-Grade Serous Ovarian Cancer
    Kim, Jaeyeon
    Park, Eun Young
    Kim, Olga
    Schilder, Jeanne M.
    Coffey, Donna M.
    Cho, Chi-Heum
    Bast, Robert C., Jr.
    CANCERS, 2018, 10 (11)
  • [5] High-grade serous ovarian cancer: the clone wars
    Aleksander Salomon-Perzyński
    Magdalena Salomon-Perzyńska
    Bogdan Michalski
    Violetta Skrzypulec-Plinta
    Archives of Gynecology and Obstetrics, 2017, 295 : 569 - 576
  • [6] High-grade serous ovarian cancer: the clone wars
    Salomon-Perzynski, Aleksander
    Salomon-Perzynska, Magdalena
    Michalski, Bogdan
    Skrzypulec-Plinta, Violetta
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2017, 295 (03) : 569 - 576
  • [7] The role of Apela in high-grade serous ovarian cancer
    Daily, Laura R.
    Ganguly, Debolina
    Hayes, D. Neil
    Wang, Yinan
    Sims, Michelle M.
    Cheng, Jinjun
    ElNaggar, Adam C.
    Pfeffer, Lawrence M.
    CANCER RESEARCH, 2018, 78 (13)
  • [8] Drugs Repurposing in High-Grade Serous Ovarian Cancer
    Torralba, Manuel
    Farra, Rossella
    Maddaloni, Marianna
    Grassi, Mario
    Dapas, Barbara
    Grassi, Gabriele
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (42) : 7222 - 7233
  • [9] Principles of dormancy evident in high-grade serous ovarian cancer
    Trevor G. Shepherd
    Frederick A. Dick
    Cell Division, 17
  • [10] The peritoneal tumour microenvironment of high-grade serous ovarian cancer
    Leinster, D. Andrew
    Kulbe, Hagen
    Everitt, Gemma
    Thompson, Richard
    Perretti, Mauro
    Gavins, Felicity N. E.
    Cooper, Dianne
    Gould, David
    Ennis, Darren P.
    Lockley, Michelle
    McNeish, Iain A.
    Nourshargh, Sussan
    Balkwill, Frances R.
    JOURNAL OF PATHOLOGY, 2012, 227 (02): : 136 - 145